drugset / Trial / NCT00635323
Safety And Efficacy Of Irinotecan Plus Capecitabine As First-Line Treatment In Asian Subjects With Hepatocellular Carcinoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To evaluate the safety and efficacy of irinotecan and capecitabine in Asian subjects with inoperable hepatocellular carcinoma.
Timeline
- Start
- 2002-11
- Primary completion
- —
- Completion
- 2005-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Subject | Irinotecan | Small molecule | 200 mg/m2 | Intravenous |
| Subject | Irinotecan | Small molecule | 250 mg/m2 | Intravenous |